GlobeNewswire by notified

Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases


PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor. The course of NMOSD is driven by episodes of severe, sequential relapses leading to the accrual of permanent disability, while gMG is characterized by a heterogeneous collection of symptoms (including fatigue and muscle group weakness) which fluctuate over time.

Currently, no objective measurement tools exist to allow gMG and NMOSD patients to track their symptoms over time. Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms. If clinically validated, these measures could provide data to improve the remote monitoring of disease symptoms.

"We believe that empowering patients through real-time digital data sharing could strengthen communication between patients and healthcare professionals, and may enable more informed disease management decisions," said Dr. Guido Sabatella, Global Medical Lead in Neurology at Alexion. 

"Easy-to-use digital tools have the potential to generate reliable and objective data to better understand the real impact of the disease on patients' lives and also have the potential to demonstrate the benefits of novel therapies to keep disease under control," explains Matthieu Lamy, Ad Scientiam's President.

Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG. Ongoing research will inform the development of a digital medical device intended to be used by patients as a self-assessment tool.

"International, multicenter, comparative studies against clinical gold standards, such as the Quantitative Myasthenia Gravis score and assessments of visual function, ambulation and dexterity in NMOSD, will be deployed to confirm the clinical relevance of selected digital biomarkers," according to Dr. Saad Zinaï, Ad Scientiam's Chief Medical Officer.

About Ad Scientiam 

We strongly believe that continuously monitoring the progression of severe and disabling diseases in real life is crucial for delivering better care. 

To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through smartphones and transformed using proprietary algorithms.

Hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies, including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis, trust us. In 2019, we launched MSCopilot®, the first CE-marked software medical device for the self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.

Check our LinkedIn and Facebook page, or visit

Press contact:

Contact Information:
Saad Zinaï
Chief Medical Officer

Matthieu Lamy

Related Files

FEB2023_Ad Scientiam digital biomarkers PR_Final_for Newswire.pdf

Related Images

To view this piece of content from, please give your consent at the top of this page.

Image 1: Ad Scientiam Logo

This content was issued through the press release distribution service at


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Adfenix skifter navn til Realforce20.3.2023 16:51:13 CET | pressemeddelelse

Efter to vigtige opkøb tager marketingselskabet for fast ejendom, Adfenix, et nyt navn og bliver den første platform af sin art med marketingaktiviteter rettet mod fast ejendom. GØTEBORG, Sverige, March 20, 2023 (GLOBE NEWSWIRE) -- Adfenix, der anvendes af tusindvis af ejendomsmæglere over hele verden, har længe været kendt for sine yderst effektive annoncekampagner på de sociale medier og sin evne til at generere kunder. Da Adfenix inden for de sidste 18 måneder overtog kundedataselskabet Quedro og medieadministrationsselskabet Brandkeeper, gjorde Adfenix det klart, at selskabet havde ambitioner ud over annoncering på sociale medier. Det nye produktunivers under navnet Realforce er udviklet til at understøtte det undervurderede marketingteam, der har til opgave at støtte ejendomsmæglere med deres markedsføringsbehov. Realforce er organiseret, automatiseret, AI-drevet, dataunderstøttet og lægger magten i hænderne på marketingfolkene til at levere førsteklasses, skalerede markedsførings

Adfenix endrer navn til Realforce20.3.2023 16:51:13 CET | Pressemelding

Etter to viktige oppkjøp får nå markedsføringsselskapet for eiendomsmeglere, Adfenix, et nytt navn som den første markedsføringsplattformen i sitt slag for fast eiendom. GØTEBORG, Sverige, March 20, 2023 (GLOBE NEWSWIRE) -- Adfenix brukes av tusenvis av eiendomsmeglere over hele verden, og har lenge vært kjent for de effektive reklamekampanjene deres på sosiale medier og evnen til å nå ut til potensielle kunder. Ved å kjøpe opp kundedataselskapet Quedro og medieadministrasjonsselskapet Brandkeeper i løpet av de siste 18 månedene har Adfenix gjort det klart at de har ambisjoner utover annonsering på sosiale medier. Det nye Realforce-produktuniverset er utviklet for å forsyne støtte til det undervurderte markedsføringsteamet, som har fått i oppdrag å hjelpe eiendomsmeglere med sistnevntes markedsføringsbehov. Organisert, automatisert, AI-drevet – Realforce er databasert og gir kontrollen til markedsførerne, slik at de kan levere førsteklasses markedsføringsløsninger i stor skala ved hjel

Nokia Corporation - Managers' transactions (Batra)20.3.2023 16:30:00 CET | Press release

Nokia Corporation Managers’ transactions 20 March 2023 at 17:30 EET Nokia Corporation - Managers' transactions (Batra) Transaction notification under Article 19 of EU Market Abuse Regulation. ____________________________________________ Person subject to the notification requirement Name: Batra, Nishant Position: Other senior manager Issuer: Nokia Corporation LEI: 549300A0JPRWG1KI7U06 Notification type: INITIAL NOTIFICATION Reference number: 27664/9/4 ____________________________________________ Transaction date: 2023-03-20 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009000681 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 70000 Unit price: 4.26058 EUR Aggregated transactions (1): Volume: 70000 Volume weighted average price: 4.26058 EUR About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, f